<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSESecond malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (SMNs) after diagnosis of childhood <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) are rare events </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODSWe analyzed data on risk factors and outcomes of 642 children with SMNs occurring after treatment for ALL from 18 collaborative study groups between 1980 and 2007.ResultsAcute myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n = 186), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; n = 69), and nonmeningioma <z:mp ids='MP_0009277'>brain tumor</z:mp> (n = 116) were the most common types of SMNs and had the poorest outcome (5-year survival rate, 18.1% ± 2.9%, 31.1% ± 6.2%, and 18.3% ± 3.8%, respectively) </plain></SENT>
<SENT sid="2" pm="."><plain>Five-year survival estimates for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were 11.2% ± 2.9% for 125 patients diagnosed before 2000 and 34.1% ± 6.3% for 61 patients diagnosed after 2000 (P &lt; .001); 5-year survival estimates for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were 17.1% ± 6.4% (n = 36) and 48.2% ± 10.6% (n = 33; P = .005) </plain></SENT>
<SENT sid="3" pm="."><plain>Allogeneic stem-cell transplantation failed to improve outcome of secondary <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> after adjusting for waiting time to transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>Five-year survival rates were above 90% for patients with <z:hpo ids='HP_0002858'>meningioma</z:hpo>, Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0002890'>thyroid carcinoma</z:hpo>, <z:hpo ids='HP_0002671'>basal cell carcinoma</z:hpo>, and <z:e sem="disease" ids="C0030581" disease_type="Neoplastic Process" abbrv="">parotid gland tumor</z:e>, and 68.5% ± 6.4% for those with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Eighty-nine percent of patients with <z:mp ids='MP_0009277'>brain tumors</z:mp> had received cranial irradiation </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">Solid tumors</z:e> were associated with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> exposure, and <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancy</z:e> was associated with <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> and starting doses of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> of at least 25 mg/m(2) per week and <z:chebi fb="0" ids="50667">mercaptopurine</z:chebi> of at least 75 mg/m(2) per day </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">Myeloid malignancies</z:e> with <z:mp ids='MP_0004026'>monosomy</z:mp> 7/5q- were associated with high hyperdiploid ALL karyotypes, whereas 11q23/MLL-rearranged <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was associated with ALL harboring translocations of t(9;22), t(4;11), t(1;19), and t(12;21) (P = .03) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONSMNs, except for <z:mp ids='MP_0009277'>brain tumors</z:mp>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, have outcomes similar to their primary counterparts </plain></SENT>
</text></document>